BRIDGEBIO PHARMA'S AFFILIATE QED THERAPEUTICS AND HELSINN GROUP ANNOUNCE STRATEGIC COLLABORATION

Posted on 2 April 2021

Category: Corporate

Tags: Antonella Bennici, BridgeBio Pharma, Helsinn Group, Matteo Missaglia, Slider

BridgeBio Pharma, through its affiliate QED Therapeutics, and Helsinn Group announced a global collaboration and licensing agreement to further develop and commercialize QED Therapeutics' FGFR1-3 inhibitor, infigratinib, in oncology and all other indications except for skeletal dysplasias (including achondroplasia). Completion of the agreement is subject to regulatory review and customary closing conditions, which are expected to occur in the second quarter of 2021.

Under the terms of the agreement, BridgeBio will retain all rights to infigratinib in skeletal dysplasia, including achondroplasia. Subject to U.S. Food and Drug Administration ("FDA") approval, QED and Helsinn will co-commercialize infigratinib in oncology indications in the U.S. and will share profits and losses on a 50:50 basis. Helsinn will have exclusive commercialization rights and lead commercialization for infigratinib in non-skeletal dysplasia indications outside of the U.S., excluding China, Hong Kong and Macau, which are covered by BridgeBio's strategic development and commercialization collaboration with LianBio. Under the Agreement, BridgeBio will be eligible to receive more than $2 billion in upfront, regulatory and commercial milestones, as well as tiered royalties on adjusted net sales from Helsinn Group.

Legal aspects of the deal were followed by the General Counsel Matteo Missaglia (pictured) and Antonella Bennici, BD and Corporate Legal Director.